Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Accured Expenses (2016 - 2025)

Fennec Pharmaceuticals filings provide 12 years of Change in Accured Expenses readings, the most recent being $1.9 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 1581.74% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 776.99% increase, with the full-year FY2025 number at $2.2 million, up 776.99% from a year prior.
  • Change in Accured Expenses hit $1.9 million in Q4 2025 for Fennec Pharmaceuticals, up from $1.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q4 2025 to a low of -$1.3 million in Q2 2024.
  • Median Change in Accured Expenses over the past 5 years was -$75000.0 (2023), compared with a mean of $229470.6.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 1666.67% in 2024 and later soared 1581.74% in 2025.
  • Fennec Pharmaceuticals' Change in Accured Expenses stood at $689000.0 in 2021, then skyrocketed by 164.88% to $1.8 million in 2022, then grew by 1.1% to $1.8 million in 2023, then tumbled by 93.77% to $115000.0 in 2024, then soared by 1581.74% to $1.9 million in 2025.
  • The last three reported values for Change in Accured Expenses were $1.9 million (Q4 2025), $1.5 million (Q3 2025), and -$618000.0 (Q2 2025) per Business Quant data.